Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: A retrospective follow-up

Journal of Medical Virology

Volumn 80, Issue 4, 2008, Pages 694-701

  Landro, María Eulalia ^a   Dalbert, Delia ^b   Picconi, María Alejandra ^a   Cúneo, Nicasio ^c   González, Joaquín ^a   Vornetti, Silvia ^c   Bazán, Graciela ^b   Mural, Juan ^b   Basiletti, Jorge ^a   Teyssié, Angélica Rita ^a   Alonio, Lidia Virginia ^a,d  

^a Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^b HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^c Hospital Maria Curie   (Argentina)

^d NONE   (Argentina)

Author keywords

Cervical cancer; Co factor; H ras oncogene; HPV; Lymph node; Subclinical metastasis

Indexed keywords

BIOLOGICAL MARKER; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; EARLY CANCER; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOCYTE; MACROPHAGE; MIXED INFECTION; MUTATIONAL ANALYSIS; ONCOGENE H RAS; PELVIS LYMPH NODE; PEROPERATIVE CARE; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SPECIES DISTRIBUTION; STROMA CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS TYPING; WART VIRUS;

ADULT; AGED; CELL NUCLEUS; CYTOPLASM; DNA, VIRAL; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IN SITU HYBRIDIZATION; LYMPH NODES; LYMPHOCYTES; MACROPHAGES; MIDDLE AGED; MUTATION; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 40549117888     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21076     Document Type: Article

References (49)

1. Alonio LVD, Mural D, Fernández J, Cobo M, Bazán G, Bartt O, Teyssié AR. 1990. Different papillomaviruses in uterine cervical lesions: Detection and location by "in situ" hybridization with biotynilated probes. Cervix Low Female Genital Tract 8:339-348.
2. Alonio LV, Dalbert D, Picconi MA, Cervantes Vazquez G, Garcia Carranca A, Distefano AL, Mural J, Bartt O, Bazan G, Teyssie AR. 2000. [H-ras and p53 gene mutations scanned by PCR-SSCP in premalignant and malignant lesions of the uterine cervix associated with human papillomavirus]. Medicina (B Aires) 60:895-901.
3. Alonio LV, Picconi MA, Dalbert D, Mural J, Bartt O, Bazan G, Dominguez M, Teyssie AR. 2003. H-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix. J Clin Virol 27:263-269.
4. An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH. 2005. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: A population-based study. Mod Pathol 18:528-534.
5. Baay MF, Koudstaal J, Hollema H, Duk JM, Burger MP, Quint WG, Stolz E, Herbrink P. 1997. Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer. J Clin Pathol 50:960-961.
6. Barbacid M. 1987. ras genes. Annu Rev Biochem 56:779-827.
7. Beyer-Finkler E, Girardi F, Sillem M, Pfister H. 1995. Human papillomavirus DNA in genital cancers, metastases, and lymph nodes. Intervirology 38:173-180.
8. Bishop JM. 1987. The molecular genetics of cancer. Science 235:305-311.
9. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796-802.
10. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. 2006. Preferential risk of HPV16 for squamous cell carcinoma and of HPV 18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94:171-175.
11. Burnett AF, Barnes WA, Johnson JC, Grendys E, Willett GD, Barter JF, Doniger J. 1992. Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer. Gynecol Oncol 47:343-347.
12. Cairns J. 1981. The origin of human cancers. Nature 289:353-357.
13. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. 2006. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98:303-315.
14. Chan PK, Yu MM, Cheung TH, To KF, Lo KW, Cheung JL, Tong JH. 2005. Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of patients with early stage cervical carcinoma. J Clin Virol 33:201-205.
15. Cordova-Alarcon E, Centeno F, Reyes-Esparza J, Garcia-Carranca A, Garrido E. 2005. Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch Med Res 36:311-316.
16. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76: 1057-1062.
17. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. 1994. The human H-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 91:5124-5128.
18. Fule T, Csapo Z, Mathe M, Tatrai P, Laszlo V, Papp Z, Kovalszky 1.2006. Prognostic significance of high-risk HPV status in advanced cervical cancers and pelvic lymph nodes. Gynecol Oncol 100:570-578.
19. Garuti G, Boselli F, Genazzani AR, Silvestri S, Ratti G. 1989. Detection and typing of human papillomavirus in histologic specimens by in situ hybridization with biotinylated DNA probes. Am J Clin Pathol 92:604-612.
20. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Menso S, De Nictolis M, Romanini C, Biagini G. 1998. The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: Association with 72-kilodalton metalloproteinase immunostaining. Cancer 82:886-892.
21. Grendys EC, Jr., Barnes WA, Weitzel J, Sparkowski J, Schlegel R. 1997. Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma. Gynecol Oncol 65:343-347.
22. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y. 1992. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69:72-77.
23. Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. 1995. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 33:901-905.
24. Kedzia H, Gozdzicka-Jozefiak A, Kedzia W, Poreba E. 1995. The value of the presence of HPV16 in pelvic lymph nodes of cervical cancer patients. Eur J Gynaecol Oncol 16:199-202.
25. Kiaris H, Spandidos DA. 1995. Mutations of ras genes in human tumors. Int J Oncol 7:413-421.
26. Koffa M, Koumantakis E, Ergazaki M, Malamou-Mitsi V, Spandidos DA. 1994. Detection of ras genes mutations and HPV in lesions of the human female tract reproductive tract. Int J Oncol 5:189-195.
27. Lukaszuk K, Liss J, Wozniak I, Sliwinski W, Emerich J, Wojcikowski C. 2004. HPV and histological status of pelvic lymph node metastases in cervical cancer: A prospective study. J Clin Pathol 57:472-476.
28. Lukaszuk K, Liss J, Gulczynski J, Nowaczyk M, Nakonieczny M, Piatkowski M, Sliwinski W, Baay M, Wozniak I, Maj B, Lukaszuk M. 2007. Predictive value of HPV DNA in lymph nodes in surgically treated cervical carcinoma patients - A prospective study. Gynecol Oncol 104:721-726.
29. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. 2002. Ras family genes: An interesting link between cell cycle and cancer. J Cell Physiol 192:125-130.
30. Maniatis T, Fritsch EF, Sambrook J. 1989. Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory.
31. Medina-Martinez O, Vallejo V, Guido MC, Garcia-Carranca A. 1997. H-ras oncogene-induced transcription of human papillomavirus type 18 E6 and E7 oncogenes. Mol Carcinog 19:83-90.
32. Moore DH. 2006. Cervical cancer. Obstet Gynecol 107:1152-1161.
33. Park JS, Chee YH, Namkoong SE, Han SK, Kim TE, Lee HY, Kim SJ. 1994. Human papillomavirus detection in cervical carcinoma tissues and paraaortic lymph nodes by the polymerase chain reaction. Gynecol Oncol 53:344-351.
34. Picconi MA, Eijan AM, Distefano AL, Pueyo S, Alonio LV, Gorostidi S, Teyssie AR, Casabe A. 2000. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: Analysis of primary tumors and lymph nodes. J Med Virol 61:65-69.
35. Rosen S, Skaletsky HJ. 2000. Primer 3 on the WWW for general users and for biologist programmers. In: (Krawetz S, Misener S (eds). Bioinformatics methods and protocols: Methods in molecular biology. Totowa, NJ: Humana Press, pp 365-386.
36. Saiki RK. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.
37. Satoh T, Nakafuku M, Kaziro Y. 1992. Function of Ras as a molecular switch in signal transduction. J Biol Chem 267:24149-24152.
38. Sherbet GV, Patil D. 2003. Genetic abnormalities of cell proliferation, invasion and metastasis, with special reference to gynaecological cancers. Anticancer Res 23:1357-1371.
39. Soh LT, Heng D, Lee IW, Ho TH, Hui KM. 2002. The relevance of oncogenes as prognostic markers in cervical cancer. Int J Gynecol Cancer 12:465-474.
40. Stenzel A, Semczuk A, Rozynskal K, Jakowicki J, Wojcierowski J. 2001. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: A study of 31 cases. Pathol Res Pract 197:597-603.
41. Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L. 1988. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 7:1815-1820.
42. Tenti P, Romagnoli S, Silini E, Pellegata NS, Zappatore R, Spinillo A, Zara C, Ranzani GN, Carnevali L. 1995. Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix. Int J Cancer 64:9-13.
43. Tindle RW. 2002. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59-65.
44. Tonon SA, Picconi MA, Zinovich JB, Liotta DJ, Bos PD, Galuppo JA, Alonio LV, Ferreras JA, Teyssie AR. 1999. Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma. Infect Dis Obstet Gynecol 7:237-243.
45. van Bommel PF, van den Brule AJ, Helmerhorst TJ, Gallee MP, Gaarenstroom KN, Walboomers JM, Meijer CJ, Kenemans P. 1993. HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer. Gynecol Oncol 48:333-337.
46. Van Le L, Stoerker J, Rinehart CA, Fowler WC. 1993. H-ras codon 12 mutation in cervical dysplasia. Gynecol Oncol 49:181-184.
47. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
48. zur Hausen H. 1991. Viruses in human cancers. Science 254:1167-1173.
49. zur Hausen H. 2002. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.